GPR119 agonists: Novel therapeutic agents for type 2 diabetes mellitus.

摘要: Abstract Diabetes mellitus type 2 (T2D) is a group of genetically heterogeneous metabolic disorders whose frequency has gradually risen worldwide. Type started to achieve pandemic level, and it estimated that within the next decade, cases diabetes might get double due increase in aging population. rightly called 'silent killer' because emerged be one major causes, leading renal failure, loss vision; besides cardiac arrest India. Thus, clinical requirement for oral drug molecules monitoring glucose homeostasis appears unmet. GPR119 agonist, family G-protein coupled receptors, usually noticed β-cells pancreatic as well intestinal L cells, drew considerable interest (T2D). monitors physiological mechanisms enhance glucose, such glucose-like peptide-1, gastrointestinal incretin hormone levels, beta cell-dependent insulin secretion glucose-dependent insulinotropic peptide (GIP). In this manuscript, we have reviewed work done last five years (2015–2020) which gives an approach design, synthesize, evaluate study structural activity relationship novel agonist-based lead compounds. Our article would help researchers guide their endeavours direction strategy development innovative, effective compounds management 2.